Table 3.
Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Patient HIV Infection Characteristics and Central Nervous System Penetration Effectiveness (CPE) Score
| HIV Infection Characteristics and CPE Score | NAMACO Study (N = 909) |
|---|---|
| Current CD4 cell count (cell/μL) median (IQR) | 638 (473–822) |
| Nadir CD4 cell count (cell/μL) | |
| Continuous median (IQR) | 180 (73–268) |
| <200, n (%) | 510 (56.1) |
| ≥200, n (%) | 399 (43.9) |
| Time since ART initiation (years), median (IQR) | 12 (6–18) |
| ART regimenc, n (%) | |
| Nucleoside reverse-transcriptase inhibitor | 868 (95.5) |
| Nonnucleoside reverse-transcriptase inhibitor | 451 (49.6) |
| Protease inhibitor | 395 (43.5) |
| Integrase inhibitor | 238 (26.2) |
| Entry/fusion inhibitor | 19 (2.1) |
| Cross-Sectional CPE Score | |
| Continuous median (IQR) | 7 (7–8) |
| <7, n (%) | 189 (20.8) |
| ≥7, n (%) | 720 (79.2) |
| Total, n (%) | 909 (100.0) |
| ≤5, n (%) | 38 (4.1) |
| 6–8, n (%) | 654 (72.0) |
| ≥9, n (%) | 217 (23.9) |
| Total, n (%) | 909 (100.0) |
| Cumulative CPE Score (Entire ART Duration)d | |
| Mean daily CPE score, median (IQR) | 6.66 (5.67–7.39) |
| Percent ART days spent with CPE score <7, median (IQR) | 31.8 (1.9–58.6) |
| Percent ART days spent with CPE score ≥7, median (IQR) | 68.2 (41.4–98.1) |
| Percent ART days spent with CPE score ≤5, median (IQR) | 15.3 (0.0–38.8) |
| Percent ART days spent with CPE score 6–8, median (IQR) | 57.0 (29.8–93.5) |
| Percent ART days spent with CPE score ≥9, median (IQR) | 8.1 (0.0–36.5) |
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range.
aAt the time of neurocognitive assessment.
bAmong patients with detectable viremia (≥50 copies/mL).
cART regimen at the time of baseline neurocognitive assessment.
dNote that the values expressed are median percentages of days spent with CPE scores within a certain group. In this way, the median percentages calculated when there are more than 2 CPE score groups (that is, in the case of ≤5, 6–8, and ≥9) will not have a final sum of 100%.